Latest / This Week In Medicine / 9 29 2025

Transcript

9 29 2025 · This Week In Medicine

• 0:00
  [SPEAKER_00]: Welcome to this week in medicine, your filtered medical journal summary.
• 0:03
  [SPEAKER_00]: Looking to stay up to date with the latest medical research but short on time?
• 0:07
  [SPEAKER_00]: This week in medicine has you covered.
• 0:09
  [SPEAKER_00]: Our AI-generated podcast provides you with a convenient, on the go-solution to keep you informed about the most significant developments in the medicine field.
• 0:16
  [SPEAKER_00]: Each episode offers a filtered and concentrated summary of key journal articles, allowing you to stay informed without the need to sift through pages of research papers.
• 0:24
  [SPEAKER_00]: With this week in medicine, listening is faster than reading, and you can consume valuable medical knowledge while commuting, exercising, or during your daily routine.
• 0:32
  [SPEAKER_01]: Hi, this week in medicine, we will be discussing.
• 0:35
  [SPEAKER_01]: First we will be discussing articles in New England Journal of Medicine.
• 0:39
  [SPEAKER_01]: Digitoxin and patients with heart failure and reduced ejection fraction.
• 0:43
  [SPEAKER_01]: Background The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established conclusions.
• 0:54
  [SPEAKER_01]: Treatment with Digitoxin led to a lower combined risk of death from any cause or hospital admission for worsening heart failure, than placebo among patients with heart failure and reduced ejection fraction, who received guideline-directed medical therapy.
• 1:09
  [SPEAKER_01]: Next, a pixaban for extended treatment of provoked Venus thromboembolism.
• 1:14
  [SPEAKER_01]: Background
• 1:15
  [SPEAKER_01]: The appropriate duration of anti-coagulation for Venus thromboembalism, VTE.
• 1:20
  [SPEAKER_01]: In patients who have a transient provoking factor, for example surgery, trauma, or immobility, and concomitant enduring risk factors is uncertain conclusions.
• 1:31
  [SPEAKER_01]: Among patients with provoked VTE and enduring risk factors, low intensity therapy with epicsaban for 12 months resulted in a lower risk of symptomatic recurrent VTE
• 1:45
  [SPEAKER_01]: Next, measurable residual disease guided therapy for chronic lymphocytic leukemia.
• 1:51
  [SPEAKER_01]: Backgrounded.
• 1:53
  [SPEAKER_01]: An interiminalysis of progression-free survival in this trial showed that Ibrutinib venetoclax was superior to flutera-been cyclophosphomide retoxamab, FCR, among patients with chronic lymphocytic leukemia, CLL, whether Ibrutinib venetoclax is more effective than Ibrutinib
• 2:13
  [SPEAKER_01]: With extended follow-up and increased enrollment, our trials showed that undetectable MRD and extended progression free survival were more common with Ibrutinib Venetoclacks than with Ibrutinib alone or FCR.
• 2:25
  [SPEAKER_01]: The results for overall survival were also consistent with a benefit of Ibrutinib Venetoclacks.
• 2:31
  [SPEAKER_01]: Next, early Tyrophibon infusion after intravenous thromboluses for stroke.
• 2:37
  [SPEAKER_01]: Background.
• 2:38
  [SPEAKER_01]: Intravenous thromboluses remains a standard treatment for acute eschemic stroke within 4.5 hours after onset.
• 2:45
  [SPEAKER_01]: Vascular reaclusion may occur after intravenous thromboluses and may be preventable with an anti-platelet agent within the first 24 hours after thromboluses.
• 2:54
  [SPEAKER_01]: Tyrophibon, a platelet glycoprotein iib fire receptor antagonist, has reduced macro-vascular reaclusion in experimental models' conclusions.
• 3:05
  [SPEAKER_01]: In patients with acute ischemic non-cardiombalic stroke who underwent thromboluses within 4.5 hours after onset, early Tyrophibon increased the likelihood of an excellent functional outcome.
• 3:16
  [SPEAKER_01]: The incidence of intracranial hemorrhage was low
• 3:28
  [SPEAKER_01]: Next, we will be discussing articles from Journal of American Medical Association.
• 3:32
  [SPEAKER_01]: Leave Adopa added to Stroke Rehabilitation.
• 3:35
  [SPEAKER_01]: Question.
• 3:36
  [SPEAKER_01]: Does leave Adopa therapy added to standardized rehabilitation improve stroke recovery compared with standardized rehabilitation alone?
• 3:44
  [SPEAKER_01]: Findings.
• 3:45
  [SPEAKER_01]: In this randomized clinical trial, including 610 participants, motor function at three months, measured by the Fugle-Mire Assessment Total Score, was not significantly different between the LevaDopa plus standardized rehabilitation group, compared with the placebo plus standardized rehabilitation group.
• 4:02
  [SPEAKER_01]: Median, 68 points versus 64 points respectively, adjusted mean between group difference, minus 0.90 points, meaning these results do not support routine use of Levedopa for motor recovery and unselected patients with stroke undergoing rehabilitation.
• 4:24
  [SPEAKER_01]: Next we will be discussing articles from Annals of Internal Medicine.
• 4:28
  [SPEAKER_01]: Palliative care educational app for family caregivers of homebound patients with incurable cancer, a single center randomized trial.
• 4:36
  [SPEAKER_01]: Background Home-based palliative care relies on empowered family caregivers to overcome the limited availability of palliative care professional resources.
• 4:46
  [SPEAKER_01]: In managing and curable cancer-tons conclusion, the palliative care educational app through we chat improved hercle among patients with incurable cancer at two months.
• 4:56
  [SPEAKER_01]: This finding has implications for future study and development.
• 5:06
  [SPEAKER_01]: Next we will be discussing articles from British Medical Journal.
• 5:09
  [SPEAKER_01]: First mammography screening participation and breast cancer incidents and mortality in the subsequent 25 years.
• 5:16
  [SPEAKER_01]: Objective to determine whether women who did not attend their first mammography screening invitation have a long-term risk of poor screening adherence and breast cancer outcomes.
• 5:26
  [SPEAKER_01]: Conclusions, this study shows that first screening non-participants represent a large population
• 5:34
  [SPEAKER_01]: Providing an opportunity for targeted interventions to improve adherence to screening, and thereby decrease mortality risk.
• 5:46
  [SPEAKER_01]: Next we will be discussing articles from Lancet.
• 5:49
  [SPEAKER_01]: Minimum effective low dose of antithamocyc labulin in people aged 5 to 25 years with recent onset stage 3 type 1 diabetes, meld ATG, a phase 2, multi-center, double-blind, randomized, placebo-controlled, adaptive dose-ranging trial.
• 6:06
  [SPEAKER_01]: Background
• 6:07
  [SPEAKER_01]: Type 1 diabetes remains an important health care problem.
• 6:11
  [SPEAKER_01]: With no disease modifying therapies available in people with recent onset, clinical type 1 diabetes.
• 6:17
  [SPEAKER_01]: Adaptive trial designs, allowing faster evaluation of treatment modalities, remain underexplored in this stage of the disease.
• 6:25
  [SPEAKER_01]: We aimed to identify the minimum effect of dose of antithamocyte globulin, ATG.
• 6:30
  [SPEAKER_01]: In people aged 5 to 25 years with recent onset, clinical-type 1 diabetes dot interpretation.
• 6:37
  [SPEAKER_01]: In young people with recent onset, clinical-type 1 diabetes, 2-middle-dot-5-mila-gram-slash-kg, and 0-middle-dot-5-mila-gram-slash-kg-atg, reduced loss of beta cell function, showing the potential of an affordable, repurposed agent, ATG, in a low and safe dose, as a disease modifying agent
• 7:05
  [SPEAKER_01]: Next, we will be discussing articles in the field of hematology.
• 7:09
  [SPEAKER_01]: Here are the articles from JAMA oncology.
• 7:12
  [SPEAKER_01]: Riboseclib plus endocrine therapy in hormone receptor positive slash ERBB2 negative early breast cancer.
• 7:19
  [SPEAKER_01]: Question is the efficacy benefit of riboseclib sustained beyond the planned three-year treatment duration for patients with hormone receptor positive slash ERBB2, formerly her two negative
• 7:34
  [SPEAKER_01]: Findings.
• 7:35
  [SPEAKER_01]: In this exploratory four-year analysis of 5,101 patients from the Natalie trial, riboseclib, plus a non-steroidal aromatase inhibitor, NSAI, continued to demonstrate an invasive disease-free survival, and distant disease-free survival benefit over and
• 8:02
  [SPEAKER_01]: Meaning Natalie results continue to support the benefit of adding 3 years of riboseclib to a Juventin sigh in patients with hormone receptor, positive slash ERBB2 negative early breast cancer at risk of recurrence.
• 8:21
  [SPEAKER_01]: Next we will be discussing articles in the field of rheumatology.
• 8:24
  [SPEAKER_01]: Severe maternal morbidity during and after pregnancy among veterans with systemic lupus or rheumatosis or rheumatoid arthritis.
• 8:32
  [SPEAKER_01]: Objective.
• 8:33
  [SPEAKER_01]: To describe severe maternal morbidity, SMM, among veterans with systemic lupus-errhythymatosis, SLE, or rheumatoid arthritis, RA, who use Department of Veterans Affairs VA Healthcare.
• 8:48
  [SPEAKER_01]: To our knowledge, this is the first study of SMM among veterans with SLE and RA.
• 8:53
  [SPEAKER_01]: Veterans with SLE appear to have an elevated risk of SMM, and veterans with SLE and RA appear to have high rates of pregnancy loss, are findings highlight the potential utility of comprehensive maternity care models for these veterans with SLE and RA within the VA health care system.
• 9:17
  [SPEAKER_01]: Next, we will be discussing articles in the field of cardiology.
• 9:20
  [SPEAKER_01]: Here are the articles from journals of the American College of Cardiology.
• 9:25
  [SPEAKER_01]: From JAMA Cardiology.
• 9:27
  [SPEAKER_01]: Institutional variability and processes of care and outcomes among patients with steamy and the US question.
• 9:33
  [SPEAKER_01]: What is the magnitude of variability in the patterns of care in patients with ST elevation, myocardial infarction, steamy, by hospital performance, location, or primary percutaneous coronary intervention, PCI, volume, and their association with outcomes, findings.
• 9:50
  [SPEAKER_01]: Results of this cross-sectional study including 73-826 patients revealed significant variability in achieving treatment times among patients with steamy across the U.S.
• 10:01
  [SPEAKER_01]: Hospitals with lower performance had worse metrics and outcomes.
• 10:05
  [SPEAKER_01]: However, outcomes were not different based on location or primary PCI volume, meaning results suggest that despite extensive evidence supporting timely steamy treatment and established national standards, coordinated strategies are needed to enhance the adoption of these benchmarks with targeted local interventions to address system-based challenges.
• 10:31
  [SPEAKER_01]: Next we will be discussing articles in the field of endocrinology.
• 10:34
  [SPEAKER_01]: Here are the articles from Journal of Clinical Endocrinology and Metabolism.
• 10:39
  [SPEAKER_01]: morbidity in males, with 45, x-slash 46, zi resembles the morbidity pattern in Turner Syndrome, a national population-based study.
• 10:50
  [SPEAKER_01]: Context
• 10:51
  [SPEAKER_01]: Pew studies have reported on males with 45, x-slash 46, zymosacism.
• 10:57
  [SPEAKER_01]: Most studies stem from pediatric settings, and knowledge of natural history and long-term health outcomes are therefore lacking.
• 11:04
  [SPEAKER_01]: To describe long-term health outcomes in males with 45, x-slash 46, zi, and comparison to the general population conclusion.
• 11:14
  [SPEAKER_01]: 45x-46, Zymosaicism in males impacts long-term health significantly.
• 11:20
  [SPEAKER_01]: The morbidity pattern includes a wide range of diseases, most known to occur at increased frequencies in Turner Syndrome.
• 11:27
  [SPEAKER_01]: The study underscores the importance of identifying these males and following them with systematic screening as in Turner Syndrome.
• 11:40
  [SPEAKER_01]: Next we will be discussing articles in the field of pulmonary and critical care.
• 11:45
  [SPEAKER_01]: Here are the articles from Chest.
• 11:47
  [SPEAKER_01]: Low intensity versus moderate intensity anti-coagulation for VinaVinus extracorporeal membrane oxygenation.
• 11:54
  [SPEAKER_01]: Background.
• 11:55
  [SPEAKER_01]: Bleeding is a common and sometimes fatal complication of VinaVinus extracorporeal membrane oxygenation, ECMO.
• 12:03
  [SPEAKER_01]: Whether lowering the intensity of anti-coagulation during vinovinesic mo is safe or effective is unknown, research question.
• 12:11
  [SPEAKER_01]: Is a large multi-center randomized trial of low intensity versus moderate intensity anti-coagulation during vinovinesic mo feasible, interpretation?
• 12:21
  [SPEAKER_01]: Our results indicate that enrollment and separation between groups are feasible in a multi-center randomized trial of low intensity, versus moderate intensity anti-quagulation, for critically ill adults receiving Vinovenous ECMO, a large multi-center randomized trial is needed and seems to be feasible.
• 12:44
  [SPEAKER_01]: Next we will be discussing articles in the field of nephrology.
• 12:47
  [SPEAKER_01]: Here are the articles from Clinical Journal of American Society of Nephrology.
• 12:52
  [SPEAKER_01]: thresholds of kidney function decline and congestion status, and their relation without comes among discharged heart failure patients.
• 12:59
  [SPEAKER_01]: The optimal balance between de-congestion and kidney function preservation remains uncertain in outpatients with heart failure.
• 13:06
  [SPEAKER_01]: Improved congestion is generally associated with lower mortality risk with EEGG for declines and only higher risk when EEG for exceeds 40%.
• 13:22
  [SPEAKER_01]: Here are the articles from Kidney International Reports.
• 13:25
  [SPEAKER_01]: A new prognostic score based on cell mediated immunity for cytomegalovirus infection after transplantation.
• 13:32
  [SPEAKER_01]: Introduction.
• 13:34
  [SPEAKER_01]: The interferon gamma, IFN gamma, enzyme linked immunosorbent spot is a highly sensitive immune assay that enables the assessment of cytomegalovirus, CMV specific cell mediated immunity,
• 13:51
  [SPEAKER_01]: However, its clinical implementation remains elusive.
• 13:54
  [SPEAKER_01]: We developed a robust CMV prognist tick score to quantify the risk of CMV infection in sought, which may be readily implemented in clinical transplantation to personalise CMV preventive therapies.
• 14:07
  [SPEAKER_01]: Next article.
• 14:08
  [SPEAKER_01]: Self-reported outcome of living kidney donation correlates with perioperative complications not with surgical techniques.
• 14:15
  [SPEAKER_01]: Introduction.
• 14:17
  [SPEAKER_01]: The German health care system lacks data on surgical complications and self-reported outcomes, SROs, of living donors, the prospective German living kidney donor registry.
• 14:27
  [SPEAKER_01]: Soul-kid GNR aims to improve the assessment of donors' medical and psychosocial risks, dot's conclusion.
• 14:34
  [SPEAKER_01]: Although the surgical technique does not directly affect donors' call shortly after donation, minimally invasive procedures result in shorter hospital stays and a quicker return to work.
• 14:44
  [SPEAKER_01]: Self-reported complications have a greater impact on mental call than those documented by transplant centers, highlighting the importance of subjective experiences during recovery.